Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Good combination therapy, alpha-blocker and imidafenacin, for Nocturia of Benign Prostatic Hyperplasia with OAB in Osaka-Hokuriku study group

Next Previous
Search
Trial Profile

Good combination therapy, alpha-blocker and imidafenacin, for Nocturia of Benign Prostatic Hyperplasia with OAB in Osaka-Hokuriku study group

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imidafenacin (Primary) ; Alpha 1 adrenergic receptor antagonists; Alpha-1a adrenergic receptor antagonists
  • Indications Benign prostatic hyperplasia; Nocturia; Overactive bladder
  • Focus Therapeutic Use
  • Acronyms GOOD-NIGHT

    • Most Recent Events

    • 24 May 2012 Results presented at the 107th Annual Meeting of the American Urological Association.
    • 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.
    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top